Serum levels of soluble CD44 in primary Sjogren's syndrome

Journal of Rheumatology

Volumn 27, Issue 6, 2000, Pages 1444-1449

  Levesque, Marc C ^a,b   Mackin, Debra A ^a   Fleming, Judith A ^a   St Clair, E William ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

CD44 antigen; Connective tissue disease; Inflammation; Sjogren's syndrome

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; SJOEGREN SYNDROME;

ADULT; ANTIGENS, CD44; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; SJOGREN'S SYNDROME;

EID: 0034130029     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Haynes BF, Telen MJ, Hale LP, Denning SM. CD44 - a molecule involved in leukocyte adherence and T-cell activation. Immunol Today 1989;10:423-8.
2. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989;56:1057-62.
3. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-13.
4. Miyake K, Underhill CB, Lesley J, Kincade PW. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 1990;172:69-75.
5. Carter WG, Wayner EA. Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 1988;263:4193-201.
6. Jalkanen S, Jalkanen M. Lymphocyte CD44 hinds the COOH-terminal heparin-hinding domain of fibronectin. J Cell Biol 1992;116:817-25.
7. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 1993;361:79-82.
8. Bennett KL, Jackson DG, Simon JC, et al. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995;128:687-98.
9. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.
10. Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993;74:257-68.
11. Gao AC, Lou W, Dong JT, et al. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Glycoconjugate profile and CD44 expression in human melanoma cell lines with different metastatic capacity. Cancer Res 1997;57:846-9.
12. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993;54:271-335.
13. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Nat Acad Sci USA 1992;89:12160-4.
14. Pierres A, Lipcey C, Mawas C, Olive D. A unique CD44 monoclonal antibody identifies a new T cell activation pathway. Eur J Immunol 1992;22:413-7.
15. Denning SM, Le PT, Singer KH, Haynes BF. Antibodies against the CD44 p80 lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol 1990;144:7-15.
16. Shimizu Y, Van Seventer GA, Siraganian R, Wahl L, Shaw S. Dual role of the CD44 molecule in T cell adhesion and activation. J Immunol 1989;143:2457-63.
17. Huet S, Groux H. Caillou B, Valentin H, Prieur AM, Bernard A. CD44 contributes to T cell activation. J Immunol 1989; 143:798-801.
18. Rothman BL, Blue ML, Kelley KA, Wunderlich D, Mierz DV, Aune TM. Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44. J Immunol 1991;147:2493-9.
19. Tan PH, Santos EB, Rossbach HC, Sandmaier BM. Enhancement of natural killer activity by an antibody to CD44. J Immunol 1993;150:812-20.
20. Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW. Monoclonal antibodies to Pgp-1/CD44 block lymphohemopoiesis in long-term bone marrow cultures. J Exp Med 1990;171:477-88.
21. St. John T, Meyer J, Idzerda R, Gallatin WM. Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 1990;60:45-52.
22. Koopman G, van Kooyk Y, de Graaff M, Meyer CJ, Figdor CG, Pals ST. Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. J Immunol 1990;145:3589-93.
23. Conrad P, Rothman BL, Kelley KA, Blue ML. Mechanism of peripheral T cell activation by coengagement of CD44 and CD2. J Immunol 1992;149:1833-9.
24. Toyama-Sorimachi N, Miyake K, Miyasaka M. Activation of CD44 induces ICAM-1/LFA-1-independent, Ca2+, Mg(2+)-independent adhesion pathway in lymphocyte-endothelial cell interaction. Eur J Immunol 1993;23:439-46.
25. Arch R, Wirth K, Hofmann M, et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992;257:682-5.
26. Camp RL, Scheynius A, Johansson C, Pure E. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. J Exp Med 1993;178:497-507.
27. Webb DS, Shimizu Y, Van Seventer GA, Shaw S, Gerrard TL. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990;249:1295-7.
28. Noble PW, Lake FR, Henson PM, Riches DW. Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages. J Clin Invest 1993;91:2368-77.
29. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996;98:2403-13.
30. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996;183:1119-30.
31. Telen MJ, Eisenbarth GS, Haynes BF. Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. J Clin Invest 1983;71:1878-86.
32. Bazil V, Horejsi V. Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand. J Immunol 1992;149:747-53.
33. Bazil V. Physiological enzymatic cleavage of leukocyte membrane molecules [see comments]. Immunol Today 1995;16:135-40.
34. Campanero MR, Pulido R, Alonso JL, et al. Down-regulation by tumor necrosis factor-alpha of neutrophil cell surface expression of the sialophorin CD43 and the hyaluronate receptor CD44 through a proteolytic mechanism. Eur J lmmunol 1991;21:3045-8.
35. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum 1991;34:1434-43.
36. Guo YJ, Liu G, Wang X, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;54:422-6.
37. Ristamaki R, Joensuu H, Salmi M, Jalkanen S. Serum CD44 in malignant lymphoma: an association with treatment response. Blood 1994;84:238-43.
38. Ristamaki R, Joensuu H, Jalkanen S. Does soluble CD44 reflect the clinical behavior of human cancer? Curr Topics Microbiol Immunol 1996;213:155-66.
39. Harn HJ, Ho LI, Shyu RY, et al. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 1996;22:107-10.
40. Folwaczny C, Noehl N, Urban S, et al. Systemic levels of soluble CD44 variant 6 (sCD44v6) in chronic inflammatory bowel disease [letter]. Am J Gastroenterol 1996;91:1680-1.
41. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
42. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
43. Aruffo A, Seed B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc Nat Acad Sci USA 1987;84:8573-7.
44. Heukeshoven J, Dernick R. Simplified method for silver staining of proteins in polyacrylamide gels and the mechanism of silver staining. Electrophoresis 1985;6:103-7.
45. Katoh S, McCarthy JB, Kincade PW. Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth. J Immunol 1994;153:3440-9.
46. St. Clair EW. New developments in Sjogren's syndrome. Curr Opin Rheumatol 1993;5:604-12.
47. Mikecz K, Brennan FR, Kim JH, Giant TT. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nature Med 1995;1:558-63.
48. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991;147:1567-74.
49. Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 1992;119:229-38.
50. Bennett TA, Lynam EB, Sklar LA, Rogelj S. Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. J Immunol 1996;156:3093-7.
51. Classen SD, Eiermann W, Wolf H, Koop R. Wilmanns W. CD44 variant in serum of breast cancer patients: a prognostic factor for clinical progression? Proc Am Assoc Cancer Res 1995;36:209.
52. Levesque MC, Haynes BF. In vitro culture of human peripheral blood monocytes induces hyaluronan binding and up-regulates monocyte variant CD44 isoform expression. J Immunol 1996;156:1557-65.
53. Haberhauer G, Kittl EM. Soluble CD44 isoform variant-5 (sCD44v5): a new serum marker in rheumatoid anhritis? [letter]. J Rheumatol 1998;25:1442-4.
54. Haberhauer G. Kittl EM. Skoumal M. et al. Increased serum levels of soluble CD44-isoform v5 in rheumatic diseases are restricted to seropositive rheumatoid arthritis. Acta Medica Austriaca 1997;24:23-5.
55. Kittl EM, Haberhauer G, Ruckser R, et al. Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatol Int 1997;16:181-6.
56. Haberhauer G, Kittl EM, Bauer K, Skoumal M, Feyertag J. Dunky A. Soluble CD44-isoform variant-5 (sCD44v5) in psoriatic arthritis [letter]. Clin Exp Rheumatol 1998;16:766-7.